Company: HROW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021562
Chunk: 90

Company: HARROW, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 2
Chunk 90
---
,025,000  
    $45,465,000  
    $26,498,000  
    $18,967,000 
  
    VEVYE 
     22,626,000  
     5,186,000  
     17,440,000  
     62,783,000  
     12,099,000  
     50,684,000 
  
    Other branded products 
     6,908,000  
     10,256,000  
     (3,348,000) 
     13,076,000  
     30,808,000  
     (17,732,000)
  
    Other revenues 
     141,000  
     228,000  
     (87,000) 
     312,000  
     375,000  
     (63,000)
  
    Branded revenue, net 
     51,582,000  
     28,552,000  
     23,030,000  
     121,636,000  
     69,780,000  
     51,856,000 
  
    ImprimisRx revenue, net 
     20,056,000  
     20,705,000  
     (649,000) 
     61,575,000  
     63,003,000  
     (1,428,000)

    Total revenues, net 
    $71,638,000  
    $49,257,000  
    $22,381,000  
    $183,211,000  
    $132,783,000  
    $50,428,000 

The
increase in revenues between periods was related to an increase in sales and units sold of IHEEZO and VEVYE during the three and nine
months ended September 30, 2025 compared to the prior year periods.

34

Cost
of Sales, Gross Profit and Gross Margin

Our
cost of sales includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients,
personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing equipment and tenant improvements depreciation,
the write-off of obsolete inventory, amortization of acquired product rights, and other related expenses.

Branded